ArticleInternational journal of general medicine2025
Machine Learning-Derived Diverse Regulated Cell Death Patterns for Therapeutic Target Identification in Glaucoma.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glaucoma is the leading cause of irreversible vision loss worldwide. We aimed to uncover the molecular mechanisms and regulatory networks of hub genes in human glaucoma to identify promising targets for detection and treatment. Methods: We obtained GSE758, GSE2378, and GSE9944 datasets from the Gene Expression Omnibus database. The list of genes linked to regulated cell death (RCD) was obtained from a previous study. RCD-related differentially expressed genes (DEGs) were identified in patients with glaucoma and controls. Weighted Gene Co-Expression Network Analysis (WGCNA) and machine learning algorithms were used to identify hub genes. Gene set enrichment analysis (GSEA) was used to explore signaling pathways enriched by hub genes, and molecular docking analysis was performed to identify the gene-drug network of hub genes for potential treatment. Immunofluorescence was used to reveal the expression levels of hub genes in glaucomatous mice and controls. Results: This study identified 358 RCD-related DEGs that distinguished healthy individuals from glaucoma patients and underscored the pivotal involvement of the immune response in human glaucoma pathogenesis. We systematically identified 33 hub genes, including PLEC, DLGAP4, Glycosylphosphatidylinositol (GPI), etc. that demonstrated significant diagnostic or treatment potential for glaucoma. The cytoskeletal regulator PLEC has emerged as a promising candidate gene associated with glaucomatous neurodegeneration with possible acting drugs. Conclusion: We constructed a machine-learning-driven analytical framework based on diverse RCD patterns to refine molecular subtypes and druggable genes. These findings may provide novel targets for glaucoma detection and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.